June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
In situ hybridization commonly identifies human papillomavirus in conjunctival papilloma but less frequently in dysplastic conjunctival neoplasms
Author Affiliations & Notes
  • Rupin Parikh
    Ophthalmic Pathology, Wilmer Eye Institute, Baltimore, Maryland, United States
  • Sepideh Siadati
    Ophthalmic Pathology, Wilmer Eye Institute, Baltimore, Maryland, United States
  • Charles Eberhart
    Ophthalmic Pathology, Wilmer Eye Institute, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Rupin Parikh, None; Sepideh Siadati, None; Charles Eberhart, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 4660. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rupin Parikh, Sepideh Siadati, Charles Eberhart; In situ hybridization commonly identifies human papillomavirus in conjunctival papilloma but less frequently in dysplastic conjunctival neoplasms. Invest. Ophthalmol. Vis. Sci. 2020;61(7):4660.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In situ hybridization provides a reliable method to detect human papillomavirus (HPV) infection, and at sites outside the eye can help to differentiate benign or low grade lesions from those with greater malignant potential. We performed a retrospective chart review to evaluate the role of HPV infections in conjunctival papilloma, conjunctival intraepithelial neoplasia (CIN), and conjunctival carcinoma in situ (CIS).

Methods : Review of institutional pathology records identified patients with a conjunctival papilloma, CIN, or CIS in which in situ hybridization was performed to detect HPV at initial diagnosis. Cases prior to 2015 were analyzed using DNA in situ hybridization (DISH), while those from 2015 onwards were analyzed using RNA in situ hybridization (RISH). The low risk HPV assay detects types 6 and 11, while the high risk assay detects HPV 16 and 18 along with additional types.

Results : Of the 46 patients in our study, 16 males and 15 females were diagnosed with conjunctival papilloma (ages 9-86, mean 42), while 8 males and 7 females were diagnosed with either CIN or CIS (ages 51-89, mean 67). Low risk HPV was identified in 24 of the 29 conjunctival papilloma tested (83%). This included 16/17 positive by RISH, and 8/12 positive by DISH. In contrast, none of the CIN/CIS cases tested were positive for low risk HPV. Only one papilloma was positive for high risk HPV, and this lesion also showed moderate to severe epithelial dysplasia. Of the two other papilloma with dysplasia, one was positive for low risk HPV and the other was negative for HPV. Among the 15 CIN/CIS cases tested, including 5 by DISH and 10 by RISH, only one was positive for high risk HPV. HPV status was not clearly linked to tumor recurrence, but a lack of long term follow up in many cases limited this analysis.

Conclusions : This study suggests that transcriptionally active low risk HPV is commonly present in conjunctival papilloma, and that RISH may be a more sensitive assay than DISH. In contrast, high risk HPV is rare in conjunctival epithelial lesions, but may promote dysplastic changes in some papilloma.

This is a 2020 ARVO Annual Meeting abstract.

 

Conjunctival papilloma with extensive low risk human papillomavirus identified by RNA in situ hybridization (20x)

Conjunctival papilloma with extensive low risk human papillomavirus identified by RNA in situ hybridization (20x)

 

Only rarely were papillomas negative for low risk human papillomavirus (20x)

Only rarely were papillomas negative for low risk human papillomavirus (20x)

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×